Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Kyndryl Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.95 (market cap $8.04B), while Kyndryl Holdings Inc trades at $11.88 (market cap $2.56B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.1× Kyndryl Holdings Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BIO | KD | |
|---|---|---|
Market Cap | $8.04B | $2.56B |
Sector | Health | Technology |
52-Week High | $339.75 | $39.47 |
52-Week Low | $241.71 | $10.59 |
Enterprise Value | $7.85B | $4.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Kyndryl Holdings (KD) trades at $12.32, up 2.92% with a bullish technical signal. The company shows improving fundamentals with 2025 net income turning positive at $252M after years of losses, though recent quarterly earnings missed expectations. Valuation remains attractive with P/E of 14.49 and EV/EBITDA of 3.19. Recent partnerships with Microsoft and AWS for AI solutions highlight strategic positioning.
Outlook remains cautiously optimistic with analyst consensus target of $14.33 offering 16% upside. Key risks include ongoing earnings volatility, internal control investigations, and high debt levels. The transformation toward higher-margin services provides growth potential, but execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
